| Project/Area Number |
14370203
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
YAMADA Masahito Kanazawa University, Graduate School of Medical Science, Professor, Department of Neurology & Aging, 医学系研究科, 教授 (80191336)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAIKI Hironobu Fukui University, Department of Pathology, Professor, 医学部, 教授 (10227704)
|
|---|
| Project Period (FY) |
2002 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥12,700,000 (Direct Cost: ¥12,700,000)
Fiscal Year 2004: ¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2003: ¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2002: ¥5,100,000 (Direct Cost: ¥5,100,000)
|
|---|
| Keywords | cerebral amyloid angiopathy (CAA) / amyloid β protein (Aβ) / Alzheimer's disease / cerebrovascular disorders / aging / geneticpolymorphism / epidemiology / anti-amyloidogenicagents / Aβ線維分解薬 / 高齢者 / 危険因子 / アミロイドβタンパク(Aβ) |
|---|
| Research Abstract |
For the purpose of development of methods of clinical diagnosis and therapies for cerebral amyloid angiopathy (CAA), we performed the following studies :
1)Clinicopathological, genetic, and epidemiological analysis of CAA :
We found assodalion of genetic polymorphisms of neprilysin and TGF-β1 with CAA. We performed a nationwide study of CAA for the first time, and identified 755 patients with CAA-related hemorrhages in recent five years.
2)Search for anti-amyloidogenic agents with an in vitro system for formation of β-amyloid (Aβ) fibrils (fAβ) :
Using an in vitro system for formation of fAβ, we found that nordihydroguaiaretic acid, nicotine, red wine-related polyphenols, curcumin, vitamin A, and tannic acid inhibit formation of fAβ, destablize preformed fAβ, and decrease cytotoxicity of fAβ.
3)Development of anti-CAA drugs using an animal model of CAA :
We administered anti-amyloidogenic agents to a transgenic animal model of Aβ type CAA for prevention or treatment of CAA ; pathological and biochemical studies are currently ongoing.
|
